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ABSTRACT 29 
 30 
 31 
Transglutaminase 2 (TG2) is a ubiquitous enzyme with transamidating activity. We 32 
report here that the expression and activity of TG2 are enhanced in cells infected with the 33 
obligate intracellular bacteria Chlamydia trachomatis. Genetic or pharmacological inhibition 34 
of TG2 activity impair bacterial development. We show that TG2 increases glucose import by 35 
up-regulating the transcription of the glucose transporter genes GLUT-1 and GLUT-3. 36 
Furthermore, TG2 activation drives one specific glucose-dependent pathway in the host, i.e. 37 
hexosamine biosynthesis. Mechanistically, we identify the glucosamine:fructose-6-phosphate 38 
amidotransferase (GFPT) among the substrates of TG2. GFPT modification by TG2 increases 39 
its enzymatic activity, resulting in higher levels of UDP-N-acetylglucosamine biosynthesis. As 40 
a consequence, TG2 activation results in increased protein O-GlcNAcylation. The correlation 41 
between TG2 transamidating activity and O-GlcNAcylation is disrupted in infected cells 42 
because host hexosamine biosynthesis is being exploited by the bacteria, in particular to assist 43 
their division. In conclusion, our work establishes TG2 as a key player in controlling glucose-44 
derived metabolic pathways in mammalian cells, themselves hijacked by C. trachomatis to 45 
sustain their own metabolic needs.  46 
 47 
 48 
KEYWORDS: Chlamydia / GFPT / Hexosamine biosynthesis / O-GlcNAcylation / 49 
Transglutaminase 2 50 
 51 
  52 
 3 
INTRODUCTION 53 
 54 
The enzyme transglutaminase 2 (TG2) is an extremely versatile protein exhibiting 55 
transamidase, protein disulfide isomerase and guanine and adenine nucleotide binding and 56 
hydrolyzing activities (Gundemir, Colak et al., 2012). Also designated as “tissue 57 
transglutaminase”, it is ubiquitously expressed in the cytoplasm and at the cell surface in 58 
association with the extracellular matrix (Eckert, Kaartinen et al., 2014). The transamidase 59 
activity is the best described activity, and it is regulated by Ca2+ (Folk, Mullooly et al., 1967). It 60 
results in the formation of cross-links between proteins, or of post-translational modification 61 
of a protein substrate through incorporation of a small primary amine, or deamidation of a 62 
glutamine into a glutamate. Under steady-state conditions, TG2 exists in a compact, inactive 63 
conformation. Increase in intracellular Ca2+ concentration (upon stress, cell activation, etc) 64 
causes a conformational change, and the enzyme becomes catalytically active as a 65 
transamidase. Studies of genetically engineered mouse models and/or inherited disorders 66 
have implicated TG2 in several pathological conditions (Iismaa, Mearns et al., 2009). In 67 
particular, increased TG2 expression and transamidation activity is a common feature of many 68 
inflammatory diseases and events (Eckert et al., 2014). Possibly linked to its increased 69 
expression in inflammatory processes, several lines of evidence suggest the involvement of 70 
TG2 during cancer development (Huang, Xu et al., 2015).  71 
Surprisingly, while the association between TG2 activity and inflammatory situations has 72 
been studied in several normal and pathological situations (Di Sabatino, Vanoli et al., 2012, 73 
Huang et al., 2015, Ientile, Curro et al., 2015, Iismaa et al., 2009, Liu, Kellems et al., 2017), the 74 
implication of this enzyme in a very classical inflammatory process, e.g. the defense response 75 
of a tissue to the invasion by a microorganism, has remained very poorly investigated. 76 
Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen, and it 77 
develops inside a vacuole in a human host cell, typically an epithelial cell of the genital tract 78 
(reviewed in (AbdelRahman & Belland, 2005)). This obligate intracellular bacterium depends 79 
on the host to supply several essential metabolites, and in particular glucose (Gehre, Gorgette 80 
et al., 2016, Stephens, Kalman et al., 1998). Epithelial cells respond to the infection with the 81 
secretion of proinflammatory cytokines such as interleukin-6 (IL-6) and IL-8 (Rasmussen, 82 
Eckmann et al., 1997). The inflammatory response is exacerbated upon reinfection, ultimately 83 
leading to tissue damage such as hydrosalpinx and fibrosis (Brunham & Rey-Ladino, 2005). In 84 
this work, we show that TG2 becomes activated during the infection of epithelial cells with C. 85 
trachomatis, and is required for optimal bacterial growth. The investigation of the 86 
consequence of TG2 activation on host metabolism and the identification of targets of TG2 87 
transamidase activity during infection uncovered the control exerted by this enzyme on 88 
glucose import and on the hexosamine biosynthesis pathway, two metabolic features that are 89 
exploited by C. trachomatis. 90 
 91 
 92 
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RESULTS 94 
 95 
TG2 is highly expressed and becomes active during C. trachomatis infection  96 
A widely-used technique to probe TG2 activation is to measure the incorporation of 97 
biotin pentylamine (BP) into proteins. When present in excess, this membrane permeable 98 
primary amine out-competes other substrates for the transamidase reaction catalyzed by TG2 99 
and becomes covalently linked to glutamine residues of TG2 substrate proteins. The biotin 100 
group is then easily detectable by western blot using streptavidin coupled to horseradish 101 
peroxidase (HRP) (Lee, Maxwell et al., 1992). This procedure was applied to HeLa cells infected 102 
or not for 48 h with C. trachomatis. In non-infected samples, BP incorporation was extremely 103 
low, as expected since in resting cells low Ca2+ concentration maintains TG2 in an inactive 104 
conformation (Gundemir et al., 2012). In contrast, infected cells showed a significant 105 
incorporation of BP. CP4d, an inhibitor of TG2 transamidating activity (Caron, Munsie et al., 106 
2012), abolished BP incorporation in a dose-dependent manner, indicating that BP 107 
incorporation was the result of the transamidase activity of TG2 (Fig. 1A). Live proliferating 108 
bacteria were needed for TG2 activation since filtered or heat-inactivated bacteria, or bacteria 109 
treated with the antibiotic doxycycline immediately after infection to prevent their 110 
proliferation, failed to induce BP incorporation (Fig. 1B and Fig. S1). BP incorporation upon 111 
infection was also observed in wild type mouse embryonic fibroblasts (MEFs) but not in MEFs 112 
isolated from tgm2 knocked-out animals (TG2-/-), further supporting the implication of TG2 in 113 
this process (Fig. 1C).   114 
Probing cellular lysates using anti-TG2 antibodies showed that activation of TG2 was 115 
accompanied with an increased expression of the enzyme (Fig. 1D). Consistent with this 116 
observation, inhibition of protein synthesis with cycloheximide decreased infection-induced 117 
BP incorporation (Fig. 1B). Reverse transcription followed by quantitative PCR (RT-qPCR) 118 
measurements revealed a 3- to 4-fold increase in the TGM2 gene transcripts in infected versus 119 
non-infected cells, demonstrating that the increase in TG2 amount during infection is at least 120 
partly controlled at the transcriptional level (Fig. 1E). Interestingly, a positive feedback loop 121 
controls in part TG2 expression since TGM2 transcription was no longer enhanced by infection 122 
when cells were treated with CP4d (Fig. 1E). TGM2 transcription responds to a number of 123 
external stimuli including retinoic acid, hypoxia, and inflammatory cytokines such as IL-6 124 
(Eckert et al., 2014, Suto, Ikura et al., 1993). We reasoned that IL-6 might be implicated in the 125 
transcriptional up-regulation of TG2 in Chlamydia infected cells as this cytokine is produced 126 
during infection (Rasmussen et al., 1997). We first verified that TGM2 transcription showed a 127 
dose-dependent response to the addition of recombinant IL-6 in the culture medium (Fig. 1F). 128 
To test if IL-6 contributes to the transcriptional up-regulation of TGM2 during infection we 129 
next performed the infection in the presence of anti-IL-6 receptor antibodies. We observed a 130 
reduction of TGM2 transcription in infected cells with increasing concentrations of antibodies 131 
in the culture medium (Fig. 1G). Altogether, these data indicate that the induction of TGM2 132 
transcription in C. trachomatis infected cells is at least in part a consequence of IL-6 secretion 133 
in response to infection, followed by signaling through the IL-6 receptor.    134 
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In conclusion, C. trachomatis infection increases TG2 levels and activates its 135 
transamidase activity. 136 
 137 
TG2 activity sustains bacterial growth 138 
To determine if TG2 activity affected bacterial development, we infected HeLa cells in 139 
the presence or not of the transamidase inhibitor CP4d. Thirty hours later, the progeny was 140 
collected and the number of infectious bacteria was determined by infecting fresh cells. 141 
Inhibition of TG2 activity with 40 µM CP4d resulted in a 2-fold decrease in bacterial progeny 142 
(Fig. 2A). Consistently, a similar reduction in bacterial progeny was observed when TG2 activity 143 
was inhibited by cysteamine, another less specific inhibitor of TG2 (Figure EV1A). Progeny was 144 
also reduced when the bacteria were grown on TG2-/- MEFs compared to TG2+/+, indicating 145 
that the effect we had observed with TG2 inhibitors was not due to a direct toxicity of CP4d 146 
or cysteamine on the bacteria (Fig. EV1B). Consistent with these observations, silencing TG2 147 
expression with two different siRNA resulted in up to a 3-fold decrease in progeny (Fig. 2B). 148 
To confirm these findings in primary cells, we used epithelial cells isolated from fallopian tubes 149 
(Roth, Konig et al., 2010). CP4d was even more potent at reducing the progeny after one 150 
developmental cycle in these cells than in HeLa cells, as a ten-fold reduction was observed for 151 
10 µM CP4d (Fig. 2C). The negative impact of TG2 inhibition on bacterial development was 152 
also observed in primary cells infected with C. trachomatis serovar D, showing that the effect 153 
is not restricted to the LGV biovar (Fig. 2C).   154 
Reduced progeny could result from impairment of one or several of the steps of the 155 
chlamydial developmental cycle: adhesion, entry, differentiation into the replicative form, 156 
proliferation, and differentiation into the infectious form. We observed that the absence of 157 
TG2 in TG2-/- MEFs had no effect on bacterial adhesion (Fig. EV1C), but that it decreased the 158 
efficiency of bacterial internalization (Fig. EV1D). Consistently, 40 µM CP4d decreased the 159 
percentage of infected cells by about 2-fold in HeLa cells (Fig. 2D). In addition, inclusions were 160 
smaller in cells treated with CP4d, and contained less bacteria, indicating that bacterial growth 161 
was slower in the absence of TG2 activity (Fig. 2D). The reduction of inclusion size when TG2 162 
was inhibited was also observed in primary cells infected with C. trachomatis L2 or serovar D 163 
(Fig. 2E).    164 
We next tested the incidence of the absence of TG2 on chlamydial development in a 165 
mouse model of infection. Chlamydia muridarum is a mouse-adapted strain genetically very 166 
close to C. trachomatis (Read, Brunham et al., 2000). Infection of HeLa cells with C. muridarum 167 
also activated TG2 (Fig. EV2A), and we observed the same effect of silencing TG2 on C. 168 
muridarum growth as on C. trachomatis (Fig. EV2B). We infected TG2+/+ and TG2-/- mice 169 
intravaginally with C. muridarum and 25 days after infection, mice were sacrificed and the 170 
genital tract was isolated (Fig. 2F). DNA was extracted from the upper genital tract and 171 
bacterial load was determined by qPCR. A slightly higher number of mice retained detectable 172 
bacterial DNA in the wild type group (10/16, 62 %, for the TG2+/+ and 4/9, 44% for the TG2-/- 173 
mice). Among the animals in which bacterial DNA was still detected, the trend was for a higher 174 
bacterial load in the wild type background, but the number of TG2-/- animals we could breed 175 
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was too low for statistical significance. These data indicate that the absence of TG2 reduces 176 
only marginally, if at all, the ability for C. muridarum to establish an infection. It is however 177 
possible that in some tissues the loss of TG2 is compensated by expression of other 178 
transglutaminases, limiting the interpretation of these data (Iismaa et al., 2009). One clear 179 
difference between the two groups came from anatomical observations: TG2-/- animals 180 
showed milder signs of inflammation than their wild type littermate, especially when the 181 
oviduct hydrosalpinx scores were compared. It thus appears that the presence of TG2 182 
exacerbates the tissue damage in this mouse model of infection, in line with the implication 183 
of TG2 in tissue fibrosis (Eckert et al., 2014, Iismaa et al., 2009).  184 
 185 
TG2 plays a central role in metabolic rewiring  186 
We have recently shown that C. trachomatis acts as a glucose sink (Gehre et al., 2016). 187 
The host cell responds to glucose demand by increasing glucose uptake through 188 
overexpression of plasma membrane glucose transporters (Ojcius, Degani et al., 1998, Wang, 189 
Hybiske et al., 2017). Since we observed that TG2 level was increased during C. trachomatis 190 
infection, we wondered if this increase could control the concomitant increase in glucose 191 
transporter expression, as it does in mammary epithelial cells (Kumar, Donti et al., 2014). If 192 
this hypothesis was correct, one prediction that we could make was that low glucose 193 
availability in the culture medium should be more detrimental to bacterial growth in TG2-/- 194 
MEFs compared to the wild type MEFs, as TG2-/- MEFs would be impaired in their ability to 195 
adjust their glucose uptake to sustain bacterial growth. To test this hypothesis, we grew MEFs 196 
in medium containing decreasing concentrations of glucose and measured the number of 197 
infectious bacteria collected 30 hpi. As expected we observed that decreasing glucose 198 
availability resulted in a sharp decrease in bacterial titers, in both cellular backgrounds. 199 
However, bacterial titers were more sensitive to glucose deprivation in the TG2-/- MEFs than 200 
in the wild-type cells (Fig. 3A). For instance, at 1 mg/mL glucose, the progeny was reduced by 201 
82% in the TG2-/- MEFs, compared to only 35% in the TG2+/+ MEFs.  202 
To test the implication of TG2 in the rewiring of host metabolism more directly, we 203 
measured the incidence of TG2 inactivation on the cell capacity to uptake glucose. HeLa cells 204 
infected with C. trachomatis show increased transcription of GLUT-1 and GLUT-3, which allows 205 
to increase glucose uptake and meet bacterial needs (Wang et al., 2017). We reproduced this 206 
result in HeLa cells, as well as in primary cells isolated from the endocervix (Fig. 3B). In 207 
contrast, in the presence of the TG2 inhibitor CP4d, the transcription of the glucose 208 
transporter genes was no longer induced by infection, indicating that TG2 is necessary for the 209 
control of GLUT-1 and GLUT-3 transcription. Absence of increase in GLUT-1 and GLUT-3 210 
transcripts 48 hpi in the presence of CP4d was not due to the lower bacterial burden because 211 
when bacterial proliferation was interrupted 24 hpi by addition of doxycycline we observed a 212 
comparable reduction in bacterial load at 48 hpi as in cells treated with CP4d, but the 213 
transcription of the glucose transporter genes remained as high as in non-treated cells (Fig. 214 
S2).  215 
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Finally, to explore further the incidence of TG2 expression on that of glucose 216 
transporters we examined transcriptional data from a cohort of high grade serous ovarian 217 
cancer (HGSOC) patients. This population was chosen because clinical and biological data 218 
indicate that TG2 overexpression is an adverse prognostic factor in ovarian carcinoma (Hwang, 219 
Mangala et al., 2008, Shao, Cao et al., 2009). We observed a significant correlation between 220 
expression of TGM2 and GLUT-3 across the 265 clinical HGSOC specimens (ρ=0.50, P<0.001) 221 
(Fig.3C). The HGSOC cohort also demonstrated significant correlation between TG2 and GLUT-222 
1 expression, though the magnitude of correlation was less marked (ρ=0.21, P<0.001) (Fig. 223 
3C). Collectively, these data support the notion that TG2 plays a central role in regulating 224 
glucose transporters expression regulation in the context of infection or malignancy, thereby 225 
playing a central role in the control of the metabolic balance.  226 
 227 
The hypoxia-inducible factor 1 and the transamidase activity of TG2 are required for 228 
the transcriptional up-regulation of glucose transporters 229 
One major transcriptional regulator of the expression of glucose transporters is the 230 
hypoxia-inducible factor 1 (HIF-1), which is increased during Chlamydia infection (Sharma, 231 
Machuy et al., 2011). Infection did not result in an increase in HIF-1a transcripts, indicating 232 
that the increase in HIF-1 a occurs by stabilization of the transcription factor (Fig. 3D).To test 233 
whether HIF-1 was implicated in infection-induced up-regulation of glucose transport we 234 
silenced HIF-1a expression before infecting the cells. Under these conditions, we observed a 235 
loss of induction of GLUT-1 and GLUT-3 transcription in infected cells. In contrast, the increase 236 
in TGM2 transcripts upon infection remained, placing HIF-1a downstream of TGM2 induction 237 
(Fig. 3E).  238 
In the presence of the TG2 inhibitor CP4d, the transcription of the glucose transporter 239 
genes was no longer induced by infection (Fig. 3B), indicating that the transamidase activity 240 
of TG2 was required. However, this observation could also be accounted for by the inhibition 241 
that CP4d exerts on TG2 expression in infection (Fig. 1E). To address directly the role of TG2 242 
transamidase activity in the regulation of the expression of glucose transporter genes we used 243 
TG2-/- MEFS in which TG2 wild-type or mutated for the transamidase activity (C277S mutant) 244 
were constitutively expressed (Rossin, D'Eletto et al., 2012). We focused on the regulation of 245 
GLUT-1, as we did not observe an increase in GLUT-3 expression upon infection in this cellular 246 
background. Consistently with our previous findings, infection failed to induce an increase in 247 
GLUT-1 transcripts in TG2-/- MEFS (Fig. 3F). Constitutive expression of wild-type TG2, but not 248 
of the C277S mutant, restored the induction of GLUT-1 transcription upon infection. This 249 
observation demonstrates that the transamidase activity of TG2 is required for the increase 250 
in GLUT-1 transcription upon infection.  251 
Altogether, these data show that the transcription factor HIF-1, and TG2 transamidating 252 
activity, are both required for the up-regulation of glucose transporters during C. trachomatis 253 
infection. 254 
 255 
TG2 targets glutamine:fructose-6-P amidotransferase and enhances its activity  256 
 8 
In addition to its role in the up-regulation of the transcription of glucose transporter 257 
genes, TG2 may confer other benefits to C. trachomatis. To identify TG2 targets in the 258 
infectious process, HeLa cells were infected in the presence or absence of BP. Forty-eight 259 
hours later the cells were lysed and biotinylated proteins were isolated on streptavidin-coated 260 
beads, and identified by mass-spectrometry. Sixty-two proteins were found to be significantly 261 
enriched in the infected cell lysates grown in the presence of BP (Table S1). Fibronectin, 262 
galectin 3, RhoA, 40S ribosomal protein SA, immunoglobulin k chain C region and hemoglobin 263 
beta were already identified as TG2 substrates (Guilluy, Rolli-Derkinderen et al., 2007, Mehul, 264 
Bawumia et al., 1995, Nelea, Nakano et al., 2008, Orrù, Caputo et al., 2003, Pincus & Waelsch, 265 
1968, Sohn, Chae et al., 2010). BAG2 and several other mitochondrial proteins were also 266 
enriched in the samples prepared in the presence of BP, in agreement with TG2 being present 267 
and active in this compartment (Altuntas, Rossin et al., 2015).  268 
Among the potential TG2 substrates we identified in C. trachomatis infected cells, the 269 
enzyme glutamine:fructose-6-P amidotransferase (GFPT) caught our attention because it uses 270 
fructose-6-P as a substrate, which is derived from glucose-6-P. Moreover, both isoforms of 271 
the enzyme, GFPT1 (also called GFAT) and GFPT2, had been recovered from the proteomic 272 
approach, making it a very strong hit. We first confirmed that GFPT was recovered in the 273 
biotinylated fraction of cells infected with C. trachomatis in the presence of BP using anti-274 
GFPT antibodies. The abundance of GFPT in the biotinylated fraction strongly decreased when 275 
infection had been performed in the presence of the TG2 inhibitor CP4d, demonstrating that 276 
incorporation of the biotinylated probe in GFPT depended on the activity of TG2 (Fig. 4A). 277 
To further validate that GFPT is a novel substrate of TG2, purified TG2 and recombinant 278 
human GFPT1 (rhGFPT1) were incubated for 3 h at 37 °C in the presence of BP as primary 279 
amine donor. The incorporation of the biotinylated probe was analyzed by blotting with HRP-280 
coupled streptavidin. The biotinylated probe was incorporated into rhGFPT1 in the presence 281 
and not in the absence of TG2. Furthermore, chelation of Ca2+ by EGTA inhibited the 282 
incorporation of the probe, as expected for a reaction dependent on the transamidase activity 283 
of TG2 (Fig. 4B). We concluded from these experiments that GFPT is a novel substrate of TG2 284 
that becomes modified by the transamidase activity of the enzyme during C. trachomatis 285 
infection. 286 
In order to determine which glutamine residue(s) of GFPT1 was modified by TG2 in 287 
vitro, we analyzed the products of the reaction by mass spectrometry. BP incorporation was 288 
identified in ten glutamine residues (out of twenty-eight, Fig. 4C), presumably because 289 
promiscuous reactions occur in vitro. Among those, two glutamine residues were identified as 290 
prone to modification by TG2 using bioinformatics tools designed to score the peptidic 291 
environment favorable for TG2 activity, namely Q328 and Q555 (Keresztessy, Csosz et al., 292 
2006, Sugimura, Hosono et al., 2006). We thus generated a glutamine to asparagine point 293 
mutant for each of these residues to minimize the impact on protein folding. As a control, we 294 
also mutated Q58, another candidate target identified by mass spectrometry but not 295 
surrounded by a consensus sequence for TG2. Purified recombinant proteins were incubated 296 
with TG2 and BP for 30 min at 37 °C before stopping the reaction. BP incorporation was 297 
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significantly reduced only in the rhGFPT1 Q328N, indicating that the Q328 is a prominent 298 
glutamine for modification by TG2 (Fig. 4D). 299 
The fact that C. trachomatis produce their own GFPT (named GlmS) prevented us from 300 
measuring the consequence of TG2 activation on host GFPT activity in infected cells. However, 301 
ionomycin is a widely used TG2 activator, as this Ca2+ ionophore increases intracellular Ca2+ 302 
concentration, which opens TG2 in its active conformation. We thus measured GFPT activity 303 
in lysates of cells treated or not with ionomycin, and analyzed the reaction products by high 304 
performance anion exchange chromatography (Fig. S3). We observed a three-fold increase in 305 
GFPT activity in cells treated with ionomycin, indicating that GFPT modification by TG2 306 
increases the activity of the enzyme (Fig. 4E).  307 
 308 
Modification of GFPT by TG2 enhances the hexosamine biosynthesis pathway 309 
The reaction catalyzed by GFPT is the first and rate limiting step of the hexosamine 310 
biosynthesis pathway (HBP, Fig. 5A). The HBP leads to the formation of uridine 5’-diphospho-311 
N-acetylglucosamine (UDP-GlcNAc), which is further used for N-glycosylation, N-glycan 312 
branching, and O-linked N-acetylglycosylation (O-GlcNAcylation) in the ER, Golgi, and 313 
nucleus/cytosol, respectively. O-GlcNAcylation involves the transfer of a single UDP-GlcNAc 314 
moiety to the hydroxyl groups of serine or threonine residues. Two enzymes, O-315 
GlcNActransferase (OGT) and O-GlcNAcase (OGA), catalyze O-GlcNAc addition and removal, 316 
respectively and the O-GlcNAc modification level of proteins is directly dependent on the 317 
concentration of UDP-GlcNAc, the donor substrate for OGT (Kreppel & Hart, 1999). To confirm 318 
that GFPT modification by TG2 increased its activity and thus hexosamine biosynthesis we 319 
measured the level of O-GlcNAcylation in primary epithelial cells. We observed an increase in 320 
O-GlcNAcylation in cells treated with ionomycin. This increase was dependent on TG2 activity 321 
since it was not observed in the presence of the TG2 inhibitor CP4d (Fig. 5B) or in cells in which 322 
TGM2 expression had been silenced using siRNA (Fig. 5C). Altogether these experiments show 323 
that activation of TG2 transamidase activity enhances the HBP.  324 
 325 
The increase in the hexosamine biosynthetic pathway is hijacked by the bacteria  326 
Surprisingly, we did not observe an increase in O-GlcNAcylation in cells infected for 48 327 
h by C. trachomatis (Fig. 6A). Since O-GlcNAcylation directly depends on UDP-GlcNAc 328 
concentration this observation suggests that UDP-GlcNAc levels in the cytoplasm are not 329 
significantly increased in infected cells. We have previously demonstrated that C. trachomatis 330 
co-opts SLC35D2, a host antiporter transporting UDP-GlcNAc, UDP-glucose and GDP-mannose 331 
to import these metabolites into the vacuole in which the bacteria develop (Gehre et al., 332 
2016). We reasoned that UDP-GlcNAc might not accumulate in the cytoplasm in infected cells 333 
because it was relocated to the inclusion lumen. Supporting this hypothesis, we observed that 334 
activation of TG2 by ionomycin elicited a lower increase in O-GlcNAcylation in infected cells 335 
compared to non-infected cells, indicating that less free UDP-GlcNAc is available for O-336 
GlcNAcylation in the infected host cytoplasm (Fig. 6B). Importantly GFPT expression was 337 
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stable in all conditions, indicating that the decrease in O-GlcNAcylation in infected cells is not 338 
due to lower GFPT expression (Fig. 6A-B).  339 
In Gram-negative bacteria, UDP-GlcNAc supply is mostly used for lipopolysaccharide and 340 
peptidoglycan biosynthesis. C. trachomatis do not have a classical cell wall but use 341 
peptidoglycan synthesis for bacterial division (Liechti, Kuru et al., 2016). If UDP-GlcNAc, or an 342 
intermediate along the hexosamine biosynthesis pathway, was consumed at least partly in 343 
making bacterial peptidoglycan, lowering hexosamine biosynthesis should delay bacterial 344 
division, resulting in larger bacteria being formed. We tested this hypothesis by measuring the 345 
consequence of silencing GFPT, the rate-limiting enzyme in hexososamine biosynthesis, on 346 
bacterial size. The mass spectrometry data showed that both isoforms GFPT1 and GFPT2 were 347 
expressed in HeLa cells (Table S1). Comparison of the efficiency of siRNA designed to target 348 
specifically one isoform showed that GFPT2 was hardly detectable and targeting GFPT1 was 349 
sufficient to strongly decrease GFPT expression (Fig. 6C). We thus lowered hexosamine 350 
biosynthesis by treating cells with a siRNA against GFPT1 prior to infection, fixed the cells at 351 
increasing time of infection and used flow cytometry to measure bacterial sizes. As expected, 352 
the number of replicative bacteria increased with infection time (Fig. S4). Furthermore, it was 353 
recently demonstrated that replicative bacteria gradually decrease in size over the course of 354 
the developmental cycle (Lee, Enciso et al., 2017). We indeed observed a decrease in bacterial 355 
diameter over a 20 to 26 hpi time course, thereby validating the use of flow cytometry to 356 
measure the size of C. trachomatis (Fig. S4 and 6D). In cells treated with a siRNA against GFPT1 357 
the mean bacterial diameter became significantly higher than in control cells 24 hpi (Fig. 6D). 358 
We confirmed this result by measuring the diameter of bacteria on electron microscopy 359 
pictures of cells infected for 30 h (Fig. EV3). These kinetics fit well with our observation that 360 
TG2 activity increases between 24 and 48 hpi, when bacterial load is high, and access to 361 
nutrients might become limiting (Rother, Gonzalez et al., 2018). These observations support 362 
the hypothesis that a product of the hexosamine biosynthesis pathway is captured by the 363 
inclusion to support division. Consistent with a role for GFPT activity in sustaining bacterial 364 
growth we observed a reduction in the number of bacteria per inclusion 24 h post infection in 365 
the cells treated with siRNA against GFPT1, and the progeny collected was reduced 3-fold (Fig. 366 
6E). Of note, silencing of GFPT1 had no incidence on bacterial entry and the initiation of 367 
bacterial development, as the percentage of infected cells was identical to that in control cells 368 
(Fig. 6E). Altogether, these data strongly support the hypothesis that the increase in 369 
hexosamine biosynthesis by the host upon GFPT modification by TG2 is exploited by the 370 
bacteria, in particular to assist bacterial division. Interestingly, we observed that silencing TG2 371 
also increased bacterial size (Fig. 6D). While silencing TG2 has multiple effects beyond 372 
harnessing the HBP, these data are fully consistent with GFPT activation being one of the 373 
major outcomes of TG2 upregulation during C. trachomatis infection. 374 
 375 
 376 
DISCUSSION 377 
 378 
 11 
TG2 transamidase activity is very potent, and would be deleterious if not tightly 379 
controlled. In basal conditions it is mostly turned off, and it is thought that under specific stress 380 
conditions, the enzyme might be locally turned on and transamidate specific substrates. The 381 
infection with C. trachomatis provided a unique physiological situation where the expression 382 
and activity of the enzyme were increased over a relatively short period of time in a 383 
physiological set-up. We took advantage of this observation to identify TG2 substrates. Among 384 
the 62 candidates identified, we focused on the enzyme GFPT. We showed that GFPT 385 
modification by TG2 increased its activity, resulting in higher hexosamine biosynthesis, a 386 
process also fueled by the positive control exerted by TG2 on glucose transporters expression. 387 
The product of the HBP, UDP-GlcNAc, is used for post-translational modification of proteins 388 
by O-GlcNAcylation. Thus, our work uncovered an unsuspected link between TG2 389 
transamidase activity and O-GlcNAcylation. This link was disrupted in infected cells because 390 
the increase in hexosamine biosynthesis in the host was exploited by the bacteria, in particular 391 
to assist their division. In conclusion, our work establishes TG2 as a key player in controlling 392 
glucose-derived metabolic pathways in mammalian cells, themselves hijacked by C. 393 
trachomatis to sustain their own metabolic needs (Fig. 6F). 394 
Several inflammatory conditions are associated with an increase in TG2 expression 395 
(Eckert et al., 2014). We confirmed that IL-6 up-regulates TGM2 transcription (Eckert et al., 396 
2014, Suto et al., 1993) and we showed that this cytokine is implicated in the increase in TGM2 397 
transcription during C. trachomatis infection (Rasmussen et al., 1997) since anti-IL-6 receptor 398 
antibodies antagonized the induction of TG2 expression. How the enzyme becomes activated 399 
is less clear. In the cell Ca2+ concentration is high in the endoplasmic reticulum, and this 400 
compartment is tightly associated to the inclusion membrane (Derré, Swiss et al., 2011). The 401 
unfolded protein response pathway is activated in infected cells (George, Omosun et al., 402 
2016), a condition that might be sufficient to activate TG2 (Lee, Jeong et al., 2014). Indeed 403 
accumulation of cytoplasmic Ca2+ around the inclusion has been reported (Majeed, Krause et 404 
al., 1999), which might be enough to locally activate TG2.  405 
Treatment of cells with a potent inhibitor of TG2, CP4d, reduced progeny ten-fold in 406 
primary epithelial cells (Fig. 2). We have shown that the inhibition of TG2 activity had two 407 
distinct effects on C. trachomatis developmental cycle. First, it reduced the ability for the 408 
bacteria to enter the cells (Fig. S2). C. trachomatis use multiple receptors and appear to hijack 409 
several entry pathways into epithelial cells (Ford, Nans et al., 2018). The positive role played 410 
by TG2 on bacterial entry, which could be exerted from its intracellular or extracellular 411 
location, remains to be studied in future work. One attractive candidate mechanism is PDGFR 412 
signaling, since it is implicated in C. trachomatis entry (Elwell, Ceesay et al., 2008) and it is 413 
sensitive to TG2 activity (Nurminskaya, Beazley et al., 2014). Second, the inclusion developed 414 
slower in CP4d-treated culture, indicating that TG2 is necessary for optimal bacterial growth. 415 
We discuss below the two mechanisms we uncovered that account for the link between TG2 416 
activation and bacterial development, and place TG2 as a key regulator of bacterial access to 417 
glucose and its derivative UDP-GlcNAc. 418 
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We have shown that TG2 is required for the increase in transcription of GLUT-1 and 419 
GLUT-3 in infection in HeLa cells and in primary epithelial cells (Fig. 2). Glucose is an essential 420 
metabolite for C. trachomatis development and preventing the transcription of GLUT-1 and 421 
GLUT-3 by siRNA led to a two-fold decrease in progeny in HeLa cells (Wang et al., 2017). This 422 
result shows that glucose import can become limiting for bacterial growth, and thus that the 423 
control exerted by TG2 on the expression of glucose transporters accounts, at least in part, 424 
for the need for this enzyme for optimal bacterial growth. This conclusion is supported by our 425 
observation that glucose becomes limiting faster for bacterial progeny in MEFs lacking TG2 426 
than in wild-type cells. Thus, our study places TG2 as a key regulator for glucose import in 427 
infected cells. 428 
Mechanistically, we showed that HIF-1 was required for Chlamydia-induced increase in 429 
the transcription of glucose transporters. HIF-1a transcription does not increase during 430 
infection. TG2 interacts with HIF-1b (Filiano, Bailey et al., 2008), and an increase in TG2 levels 431 
upon infection might be sufficient to stabilize the HIF-1 complex. It is however not sufficient 432 
to account for infection-induced up-regulation of glucose transporters since we demonstrated 433 
that the transamidating activity of TG2 was required in this context. Through a series of 434 
elegant experiments the Johnson lab showed that the effect of TG2 on transcription was highly 435 
cell and context dependent (Gundemir, Colak et al., 2013, Gundemir, Monteagudo et al., 436 
2017). TG2 modifies several transcription factors (Gundemir et al., 2012), but none of these 437 
known targets were recovered in our proteomic approach for the identification of TG2 targets 438 
upon infection. Furthermore, it was shown very recently that TG2 enhanced chromatin 439 
binding of the general transcription factor complex TFIID through the serotonylation of 440 
histone 3 trimethylated lysine 4 (Farrelly, Thompson et al., 2019). This, or another 441 
transglutaminase-mediated histone modification, might be implicated in the transcriptional 442 
control of glucose transporter genes in the infectious context.  443 
Our proteomic approach identified 62 candidate TG2 substrates in C. trachomatis 444 
infection. Six of those were already known substrates of TG2, validating our analysis. We 445 
further demonstrated that GFPT was a substrate of TG2 and identified Q328 as a prominent 446 
transamidation site. The absence of shift in the migration profile of GFPT suggests that the 447 
amine donor is either a small protein, or a small amine, or that deamidation occurs, making 448 
identification by mass spectrometry very challenging. Experiments on GFPT 449 
immunoprecipitated from ionomycin-treated samples failed to detect histaminylation or 450 
serotonylation. Deamidation was occasionally seen on several gutamine residues, including 451 
Q328, raising questions as to the relevance of this observation that will be addressed in future 452 
studies.  453 
We showed that GFPT activity was enhanced upon transamidation by TG2. This resulted 454 
in an increase in O-GlcNAcylation, since this post-translational modification of proteins is 455 
directly dependent on the concentration of UDP-GlcNAc (Kreppel & Hart, 1999). GFPT acts as 456 
a tetramer and is negatively regulated by several post-translational modifications (Chang, Su 457 
et al., 2000, Zibrova, Vandermoere et al., 2017) and by UDP-GlcNAc (Assrir, Richez et al., 2014). 458 
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Transamidation on Gln328 could interfere with these down-regulation mechanisms and 459 
thereby unleash the HBP.  460 
Interestingly the positive correlation between TG2 activation and O-GlcNAcylation does 461 
not hold true in infected cells and our data indicate that this is due to hexosamines being 462 
consumed by the infection. Our observation that silencing GFPT expression increases bacterial 463 
diameter strongly supports the hypothesis that UDP-GlcNAc, or an intermediate along the 464 
HBP, is hijacked into the inclusion to fuel bacterial division, possibly by feeding peptidoglycan 465 
synthesis. Interestingly, a proximity-based labeling assay recently described an enrichment of 466 
TG2 and GFPT1 around the inclusion, suggesting that TG2 activation and GFPT modification 467 
might be most efficient in proximity of the bacteria-containing compartment (Olson, Widner 468 
et al., 2019). One recent publication showed that UDP-GlcNAc is also used during infection to 469 
post-translationally modify the intermediate filament vimentin and this also could contribute 470 
to significant UDP-GlcNAc consumption in C. trachomatis infection (Tarbet, Dolat et al., 2018). 471 
The role played by TG2 in viral or microbial infections is raising increasing interest. Like 472 
in the case of C. trachomatis infection, genetic or pharmacological inhibition of TG2 led to a 473 
marked reduction in Mycobacterium tuberculosis replicative capacity. However, the 474 
mechanism involved might be different, since the data suggest that reduced replication in 475 
macrophages lacking TG2 is due to the impairment of autophagy homeostasis (Palucci, Matic 476 
et al., 2017). M. tuberculosis relies largely on lipids and fatty acids as energy source, and 477 
glucose availability might not be limiting in this case (Russell, VanderVen et al., 2010). Still, up-478 
regulation of glucose transporter was also described in a mouse model of M. tuberculosis 479 
infection (Shi, Salamon et al., 2015), thus the involvement of TG2 in metabolism regulation in 480 
this context remains to be investigated.  481 
There are multiple examples of host manipulation by pathogens that shed light on 482 
fundamental cellular processes. Here our work revealed an unsuspected regulation of the HBP 483 
by TG2. This discovery has important implications. Like other post-translational modifications, 484 
protein O-GlcNAcylation dramatically alters the fate and function of target proteins. In 485 
particular transcription factors are modified by O-GlcNAcylation, which implicates this 486 
modification in transcriptional regulation (Jackson & Tjian, 1988). Physiologically, disruption 487 
of O-GlcNAcylation homeostasis has been implicated in the pathogenesis of many human 488 
diseases, which include cancer, diabetes and neurodegeneration (Jóźwiak, Forma et al., 2014, 489 
Yang & Qian, 2017). The link between TG2 and O-GlcNAcylation means that TG2 activation is 490 
expected to have broad transcriptional consequences. In particular TG2 is activated in many 491 
cancers and future investigation is required to determine the contribution of the TG2/GFPT 492 
activation axis to tumorigenesis. 493 
 494 
MATERIAL AND METHODS 495 
 496 
Cells and bacteria 497 
 498 
HeLa cells (ATCC) and mouse embryonic fibroblasts (MEFs) isolated from KO (TG2-/-) or WT 499 
(TG2+/+) C57B6 mice, were grown in Dulbecco’s modified Eagle’s medium with Glutamax 500 
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(DMEM, Invitrogen), supplemented with 10 % (v/v) heat-inactivated fetal bovine serum (FBS) 501 
(D'Eletto, Farrace et al., 2009). TG2-/- cells reconstituted with stable expression of wild  type 502 
or C277S TG2 are described in (Rossin et al., 2012). Primary cells used for experiments 503 
displayed in Fig. 2 were isolated from human fallopian tubes and maintained in culture as 504 
previously described (Roth et al., 2010). Other primary cells were isolated from endocervix 505 
biopsies of female patients and were cultivated in keratinocyte-SFM medium (Thermo Fisher 506 
Scientific) containing 50 mg.L-1 of bovine pituitary extract (Thermo Fisher Scientific) and 5 µg.L-507 
1 of epidermal growth factor (EGF) human recombinant (Thermo Fisher Scientific) (Wu et al, 508 
in preparation). All cell cultures were maintained at 37 °C, in 5 % CO2 atmosphere and were 509 
routinely tested for mycoplasma using the standard PCR method. C. trachomatis serovar LGV 510 
L2 strain 434 and serovar D/UW-3/CX (ATCC), GFP-expressing L2 (L2IncDGFP) or C. muridarum 511 
MoPn (for in vivo experiments) were propagated on HeLa cells, purified on density gradients 512 
as previously described and stored at -80 °C (Scidmore, 2005, Vromman, Laverriere et al., 513 
2014). 514 
 515 
siRNA treatment 516 
 517 
For siRNA experiments, 50 000 cells were plated in a 24-well plate and immediately mixed 518 
with Lipofectamine RNAiMAX (Invitrogen) following the manufacturer’s recommendation, 519 
using 10 nM of siRNA (Table S2). For RB size assessment, 300 000 cells were plated in a 6-well 520 
plate. For electron microscopy experiments, 1.5 million cells were plated in a 25-cm2 flask. For 521 
GFPT1 activity assay, 1 million cells were plated in a 10-cm diameter dish. The culture medium 522 
was changed the next day and experiments (infection or treatment with ionomycin) were 523 
performed two days post treatment with the siRNA. 524 
 525 
GFPT1 purification 526 
 527 
Recombinant human GFPT1 (rhGFPT1) with an internal 6-His tag was produced from a plasmid 528 
pET28-rhGFPT1-6His in E. coli Rosetta (DE3) GlmS::Tc kindly given by Dr. Badet-Denisot 529 
(Centre de Recherche de Gif, France) (Li, Roux et al., 2007).The mutated form rhGFPT1 Q58N, 530 
rhGFPT1 Q328N and rhGFPT1 Q555N were obtained using QuikChange technology (Agilent) 531 
on the plasmid pET28-rhGFPT1-6His, with primers listed in Table S2, following the 532 
manufacturer instructions, and transformed in E. coli Rosetta (DE3) GlmS::Tc. 533 
One litre of culture in 2YT medium supplemented with tetracycline (8 µg.mL-1, Sigma), 534 
kanamycin (50 µg.mL-1, Sigma), chloramphenicol (15 µg.mL-1, Sigma) and glucosamine 535 
(GlcNH2, 2 mg.mL-1, Sigma) was incubated with agitation at 37 °C until OD600 reached 0.5. 536 
Protein expression was induced by addition of 0.5 mM of isopropyl b-D-thiogalactopyranoside 537 
(Sigma) at 25 °C for 24 h before being harvested. The cell pellets were resuspended in lysis 538 
buffer (16.27 mM Na2HPO4 and 3.73 mM NaH2PO4 pH 7.5, 200 mM NaCl, 20 mM imidazole, 539 
2 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 10 % glycerol, 1 mM fructose-6-P, 540 
Roche EDTA-free protease inhibitor cocktail) and disrupted by sonication. The recombinant 541 
protein was purified by incubation with Qiagen Ni-NTA agarose beads (Qiagen) for 1 h 542 
followed by three washing steps with the lysis buffer before elution with lysis buffer 543 
containing increasing concentrations of imidazole: 30 mM, 100 mM, 175 mM and finally 500 544 
mM of imizadole. The fractions containing the protein were dialyzed against lysis buffer with 545 
20 mM HEPES replacing the phosphate buffer before storage at -80 °C  546 
 547 
TG2 activity assay 548 
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 549 
In vivo: Cells plated the day before (100 000 cells/well) were infected with C. trachomatis 550 
serovar LGV L2 at a MOI of 1, and 0.5 µM biotin pentylamine (BP) (Thermo Fisher Scientific) 551 
was added after 24 h. In some experiments, cells were pre-incubated for 2 h with 40 µM CP4d 552 
or DMSO as control before addition of bacteria. CP4d inhibits the transamidase activity of TG2 553 
(Ki = 174 nM) and favours its closed conformation (Caron et al., 2012). For experiments with 554 
ionomycin (Sigma), cells pre-treated with siRNA for 48 h or infected as described above for 24 555 
h were treated with Ionomycin and 0.5 µM BP for 6 h. 556 
At the end of the indicated incubation time, cells were lysed using 8 M urea buffer (30 mM 557 
Tris, 150 mM NaCl, 8 M urea, 1 % SDS, pH=8.0) and samples subjected to Western Blot.  558 
 559 
In vitro: 1 mU of transglutaminase from guinea pig liver (Sigma) was incubated at 37 °C for 15 560 
min or 3 h with 5 µg of rhGFPT1, rhGFPT1 Q58N or rhGFPT1 Q328N and 1 mM of BP in 20 mM 561 
HEPES buffer pH 7.5, 200 mM NaCl, 2 mM TCEP, 10 % glycerol, 1 mM fructose-6-phosphate, 562 
10 mM CaCl2. The reaction was stopped by adding ethylene-bis(oxyethylenenitrilo)tetraacetic 563 
acid (EGTA) at a final concentration of 20 mM and boiling the samples 5 min at 95 °C. 564 
 565 
Streptavidin-precipitation of TG2 targets 566 
 567 
Twenty million HeLa cells were seeded in a 163-cm2 flask. One day later, the cells were 568 
infected or not with C. trachomatis serovar LGV L2 at a MOI = 1.  Two hours post infection 569 
(hpi) the culture medium was changed and 40 µM CP4d or DMSO was added. BP was added 570 
to the culture medium at 0.5 mM 24 h post treatment (infection or not) and cells were lysed 571 
46 hpi  directly in the well using 8 M urea buffer. DNA was disrupted by sonication and a 572 
dialysis was performed against 2 M urea buffer (Tris 30 mM, NaCl 150 mM, 2 M urea, 1 % SDS, 573 
pH=8.0). Samples were incubated overnight at 4 °C with streptavidin-agarose beads (Sigma). 574 
After 3 washes with 2 M urea buffer and 3 washes with phosphate-buffered saline (PBS), 575 
proteins precipitated on the beads were eluted using Laemmli’s buffer containing 576 
dithiothreitol (Sigma) boiled 5 min at 95 °C. Samples were then analyzed by Western blot or 577 
by mass spectrometry. 578 
 579 
SDS-PAGE and Western blot 580 
 581 
Proteins were subjected to sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-582 
PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane, which was blocked 583 
with 1 x PBS containing 5 % bovine serum albumin (BSA, for biotin revelation only) or milk and 584 
0.01 % Tween 20. The membranes were then immunoblotted with primary antibodies diluted 585 
in 1 x PBS containing 5 % milk and 0.01 % Tween 20. For analyzing the TG2 activity assay, biotin 586 
incorporation was revealed using streptavidin conjugated to HRP (#RPN1231, Sigma). Primary 587 
antibodies used in the western blots were the mouse clone 7D2 against TG2 (#ABIN1109303, 588 
Covalab), rabbit anti-serum against GFPT (kindly given by Dr. C. Weigert, University of 589 
Tübingen, Germany), mouse clone RL2 against O-GlcNAcylation (#MA1-072 Thermo Fisher 590 
Scientific) and mouse clone AC-74 against β-actin (#A5441 Sigma). Secondary antibodies were 591 
anti-mouse-HRP (#NA931, GE Healthcare) or anti-rabbit-HRP (#G-21234, Invitrogen) 592 
conjugated antibodies. Blots were developed using the Western Lightning 593 
Chemiluminescence Reagent (GE Healthcare). 594 
 595 
Ovarian cancer cohort and statistical analysis 596 
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Expression data for TGM2, GLUT-1 and GLUT-3 in 265 high grade serous ovarian cancers from 597 
Edinburgh were available from previous transcriptomic studies of ovarian cancer (Hollis, 598 
Churchman et al., 2019). Per-sample expression was calculated as the mean expression of 599 
probe-sets informative for each gene. Expression comparisons were performed using 600 
Spearman’s rank correlation test. Spearman’s rank correlation was chosen over Pearson’s 601 
correlation following demonstration of non-normal expression distribution for TG2, GLUT-1 602 
and GLUT-3 (Shapiro-wilk normality test, P<0.05 for all). 603 
 604 
Mass Spectrometry 605 
 606 
In solution protein digestion: Samples were prepared in triplicate. For streptavidin-607 
precipitation of TG2 targets samples, tryptic digestion was performed by enhanced filter-608 
aided sample preparation. All steps were done in-filter. Briefly, samples were reduced (50 mM 609 
TCEP, 30 minutes at room temperature) and alkylated (50 mM iodoacetamide, 1 h at room 610 
temperature in the dark). Then, proteins were incubated overnight at 37 °C with 500bng 611 
trypsin (Trypsin Gold Mass Spectrometry Grade, Promega). Peptides were recovered by 612 
centrifugation. 613 
After TG2/GFPT1 reactions in vitro samples were diluted in a large excess of 8 M urea / 100 614 
mM Tris HCl pH 8.5 buffer and then, as previously described, reduced (5 mM TCEP, 30 minutes 615 
at room temperature) and alkylated (10 mM iodoacetamide, 30 minutes at room temperature 616 
in the dark). Proteins were first digested for 5 h at 37 °C with 500 ng rLys-C Mass Spec Grade 617 
(Promega, Madison, WI, USA) before being diluted 4-fold with 100 mM Tris HCl pH 8.5 to reach 618 
a concentration below 2 M urea. Samples were then incubated overnight at 37 °C with 500 ng 619 
Sequencing Grade Modified Trypsin (Promega, Madison, WI, USA). To achieve the complete 620 
digestion of the peptides, a second incubation with the same amount of trypsin (5 h at 37 °C) 621 
was performed. Digestion was stopped by adding formic acid to 5 % final concentration and 622 
peptides were desalted and concentrated on Sep-Pak C18SPE cartridge (Waters, Milford, MA, 623 
USA) according to manufacturer instructions. 624 
 625 
Mass spectrometry analysis: Tryptic peptides were analyzed on a Q Exactive Plus instrument 626 
(Thermo Fisher Scientific, Bremen) coupled with an EASY nLC 1 000 or 1 200 chromatography 627 
system (Thermo Fisher Scientific, Bremen). Sample was loaded on an in-house packed 50 cm 628 
nano-HPLC column (75 μm inner diameter) with C18 resin (1.9 μm particles, 100 Å pore size, 629 
Reprosil-Pur Basic C18-HD resin, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) and 630 
equilibrated in 98 % solvent A (H2O, 0.1 % FA) and 2 % solvent B (ACN, 0.1 % FA). 120 or 180 631 
min gradient of solvent B at 250 nL.min-1 flow rates were applied to separated peptides. The 632 
instrument method for the Q Exactive Plus was set up in DDA mode (Data Dependent 633 
Acquisition). After a survey scan in the Orbitrap (resolution 70 000), the 10 most intense 634 
precursor ions were selected for HCD fragmentation with a normalized collision energy set up 635 
to 28. Charge state screening was enabled, and precursors with unknown charge state or a 636 
charge state of 1 and > 7 were excluded. Dynamic exclusion was enabled for 35 or 45 seconds 637 
respectively. 638 
 639 
Data processing: Data were searched using Andromeda with MaxQuant software 1.4.1.2 or 640 
1.5.3.8 version against respectively a Chlamydia trachomatis Uniprot reference proteome 641 
database concatenated with Homo sapiens Uniprot reference proteome database. Data were 642 
also searched against usual known mass spectrometry contaminants and reversed sequences 643 
of all entries or an E. coli K12 Uniprot reference proteome database concatenated with 644 
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rhGFPT1 and gpTGase proteins (Tyanova, Temu et al., 2016). Andromeda searches were 645 
performed choosing trypsin as specific enzyme with a maximum number of two missed 646 
cleavages. Possible modifications included carbamidomethylation (Cys, fixed), oxidation (Met, 647 
variable), N-ter acetylation (variable) and BP (Gln, variable). The mass tolerance in MS was set 648 
to 20 ppm for the first search then 6 ppm for the main search and 10 ppm for the MS/MS. 649 
Maximum peptide charge was set to seven and five amino acids were required as minimum 650 
peptide length. The “match between runs” feature was applied between replicates with a 651 
maximal retention time window of 2 or 0.7 min. One unique peptide to the protein group was 652 
required for the protein identification. A false discovery rate (FDR) cutoff of 1 % was applied 653 
at the peptide and protein levels. 654 
 655 
Data analysis: To validate the identification of the BP on the glutamine of modified peptides, 656 
spectra were manually inspected (or fragment assignments).  657 
For the global quantification, output files from MaxQuant were used for protein 658 
quantification. Quantification was performed using the XIC-based LFQ algorithm with the Fast 659 
LFQ mode as described previously (Cox, Hein et al., 2014). Unique and razor peptides, included 660 
modified peptides, with at least 2 ratio count were accepted for quantification.  661 
For pairwise comparisons, proteins identified in the reverse and contaminant databases and 662 
proteins only identified by site were first discarded from the list. Then, proteins exhibiting 663 
fewer than 2 LFQ values in at least one condition were discarded from the list to avoid 664 
misidentified proteins. After log2 transformation of the leftover proteins, LFQ values were 665 
normalized by median centering within conditions (normalizeD function of the R package 666 
DAPAR (Wieczorek, Combes et al., 2017)). Remaining proteins without any LFQ value in one 667 
of both conditions have been considered as proteins quantitatively present in a condition and 668 
absent in another. They have therefore been set aside and considered as differentially 669 
abundant proteins. Next, missing values were imputed using the imp.norm function of the R 670 
package norm. Proteins with a foldchange under 2 have been considered not significantly 671 
differentially abundant. Statistical testing of the remaining proteins (having a foldchange over 672 
2) was conducted using a limma t-test thanks to the R package limma (Ritchie, Phipson et al., 673 
2015). An adaptive Benjamini-Hochberg procedure was applied on the resulting p-values 674 
thanks to the function adjust.p of R package cp4p using the robust method of Pounds and 675 
Cheng to estimate the proportion of true null hypotheses among the set of statistical tests 676 
(Pounds & Cheng, 2006). The proteins associated to an adjusted p-value inferior to an FDR 677 
level of 1% have been considered as significantly differentially abundant proteins.  678 
 679 
Adhesion assay 680 
 681 
Adhesion assays were performed as described previously (Vromman et al., 2014). In brief, 682 
MEFs cells plated in 24-well plate the day before (100 000 cells/well) were pre-cooled 30 min 683 
at 4 °C and then were incubated for 4 h at 4 °C with L2IncDGFP bacteria at a MOI = 10, sonicated 684 
prior to infection in order to disrupt bacterial aggregates. Then cells were washed gently with 685 
PBS and detached using 0.5 mM EDTA in PBS. Samples were fixed 30 min in 2 % PFA, washed 686 
with PBS and analyzed using flow cytometry. 687 
 688 
Bacterial entry assessment 689 
 690 
Entry experiments were performed as described previously (Vromman et al., 2014). In brief, 691 
MEFs cells plated on coverslips in 24-well plate the day before (100 000 cells/well) were pre-692 
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cooled 30 min at 4 °C and then incubated for 45 min at 4 °C with L2IncDGFP bacteria at a MOI 693 
= 10, sonicated prior to infection in order to disrupt bacterial aggregates. Then pre-warmed 694 
medium was added and coverslips were incubated at 37 °C before being fixed at different time 695 
points in 4 % PFA for 20 min. Extracellular bacteria were stained with a mouse anti-MOMP-696 
LPS (Argene # 11-114) antibody followed with Cy5-conjugated anti-mouse (#PA45002, 697 
Amersham Biosciences) secondary antibody. The dilutions were made in PBS containing 3 % 698 
of BSA. DNA was stained using 0.5 µg.mL-1 of Hoechst 33342 (Thermo Fisher Scientific) added 699 
in the secondary antibody solution. Images were acquired on an Axio observer Z1 microscope 700 
equipped with an ApoTomemodule (Zeiss, Germany) and a 63× Apochromat lens. Images were 701 
taken with an ORCAflash4.OLT camera (Hamamatsu, Japan) using the software Zen. 702 
 703 
Progeny assay 704 
 705 
For glucose privation tests on MEFs cells, 140 000 cells per well were seeded in a glucose-free 706 
DMEM (Invitrogen) supplemented with 10 % FBS. The following day, the medium was replaced 707 
with glucose-free DMEM supplemented with 10 % FBS and the indicated concentration of 708 
glucose (Sigma). The next day cells were infected with L2IncDGFP bacteria at a MOI = 0.2. 709 
For progeny assays on HeLa cells, primary cells or MEFs cells, 100 000 cells were seeded in a 710 
24-well plate. The next day cells were pre-treated with CP4d (or DMSO) or cysteamine 711 
(Sigma #30078) (or water) for 2 h and infected with L2IncDGFP bacteria at a MOI = 0.15. Cells 712 
treated with siRNA for 48 h were directly infected with L2IncDGFP bacteria or C. muridarum at 713 
a MOI = 0.2. Thirty hpi, cells were detached and fixed in 2 % PFA in PBS prior to flow 714 
cytometry analysis in order to evaluate the first round of infection. In duplicate wells, cells 715 
were detached, lysed using glass beads and the supernatant was used to infect new 716 
untreated cells (or WT cells in the case of MEFs) plated the day before (100 000 cells/well in 717 
a 24-well plate), in serial dilution. The next day, 3 wells per condition with an infection lower 718 
than 30 % (checked by microscopy) were detached and fixed as described above, before 719 
analysis by flow cytometry and determination of the bacterial titer. In the case of C. 720 
muridarum infections, bacteria were stained after fixation with a rabbit anti-CmGroEL 721 
antibody followed with AlexaFluor488-conjugated anti-rabbit secondary antibody (A11034, 722 
Invitrogen). Dilutions were made in PBS containing 0.1 % of BSA and 0.05 % of saponin 723 
(Sigma). The anti-CmGroEL antibody was obtained by AgroBio (La Ferté Saint-Aubain) by 724 
immunizing one New Zeland white rabbit with C. muridarum GroEL prepared as described in 725 
(Illingworth, Ramsey et al., 2011). Acquisition was performed using a CytoFLEX S (Beckman 726 
Coulter) and 50 000 events per sample were acquired and then analyzed using FlowJo 727 
(version 10.0.7). 728 
 729 
Infection in mice 730 
 731 
Female TG2-/- and TG2+/+ KO mice were kindly provided by Dr. C. Papista (INSERM UMR970, 732 
Centre de Recherche Cardiovasculaire, Paris) and maintained in the animal facility of the 733 
Institut Pasteur, Paris. All animals are treated with 2.5 mg of medroxyprogesterone (Depo-734 
provera-SCÒ, Pfizer) 7 days prior to infection to synchronize the menstrual cycle. Mice were 735 
intravaginally inoculated with C. muridarum, 105 IFU per animal. Twenty-five days after 736 
infection, animals were sacrificed and the organs excised including cervix, uterine horn and 737 
oviduct. The bacterial burden in the excised organs, in the right part of the upper genital tract 738 
was measured by qPCR after DNA extraction using the DNeasy Blood and Tissue Kit (Qiagen). 739 
The left part of the upper genital tract was excised and rinsed into PBS for the morphological 740 
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observation. Hydrosalpinx score was determined as described (Peng, Lu et al., 2011). 741 
Procedures involving mice were previously approved by local Animal Ethics Committees and 742 
registered with the French authorities (APAFIS#8635-2017012314265571).  743 
 744 
RT-qPCR and qPCR 745 
 746 
One hundred twenty-five thousand cells in a 24-well plate were infected or not with C. 747 
trachomatis serovar LGV L2 at a MOI = 1. Cells were treated with anti-IL-6 receptor antibody 748 
(Roactemra®, Roche) CP4d (40 µM) or DMSO 2 hpi, or doxycycline (62.5 ng.mL-1, Sigma) 24 749 
hpi. Cells pre-treated with siRNA for 48 h were directly infected with L2IncDGFP bacteria at a 750 
MOI = 1. For testing the response of HeLa cells to IL-6 treatment, 125 000 cells in 24-well plate 751 
were treated with recombinant human IL-6 (R&D Biosystems) for 18hrs. 752 
Total RNAs were isolated 24 or 48 hpi with the RNeasy Mini Kit (Qiagen) with DNase treatment 753 
(DNase I, Roche). RNA concentrations were determined with a spectrophotometer NanoDrop 754 
(Thermo Fisher Scientific) and normalized to equal contents. Reverse transcription (RT) was 755 
performed using the M-MLV Reverse Transcriptase (Promega) and quantitative PCR (qPCR) 756 
undertaken on the complementary DNA (cDNA) with LightCycler 480 system using LightCycler 757 
480 SYBR Green Master I (Roche). For the experiments displayed in Fig. S2, a duplicate well 758 
was used to extract genomic DNA (gDNA) of each time point using the DNeasy Blood and 759 
Tissue Kit (Qiagen). Data were analyzed using the DDCt method with the actin gene as a 760 
control gene (Schmittgen & Livak, 2008). Each RT-qPCR experiment was performed in 761 
duplicate and repeated at least three times. 762 
 763 
GFPT activity assay 764 
 765 
HeLa cells treated with ionomycin (4 µM) or DMSO for 6 h were detached in lysis buffer 766 
containing 0.05 M Tris, 0.15 M NaCl, 5 % glycerol, 0.5% NP-4, protease inhibitor cocktail EDTA-767 
free (Roche), pH 7.5. After lysis at 4 °C, NP-40 concentration was reduced by addition of an 768 
excess of reaction buffer (0.05 M Tris, 0.15 M NaCl, 5 % glycerol, protease inhibitor cocktail 769 
EDTA-free, pH 7.5) and cell debris were eliminated by centrifugation. Cell lysates were 770 
incubated 45 min at 37 °C with 0.6 mg.mL-1 fructose-6-phosphate (Sigma) and 0.6 mg.mL-1 771 
glutamine (Sigma). The reaction was stopped by incubating the samples for 5 min at 100 °C 772 
and precipitates were removed by centrifugation. Analysis of the samples was performed by 773 
high performance anion exchange chromatography (HPAEC, Dionex, model ISC3000) on a 774 
CarboPAC-PA1 column (3.2 × 250 mm, Dionex) using 100 mM NaOH, and 720 mM NaOAc in 775 
100 mM NaOH, as eluent A and B, respectively. The column was pre-equilibrated for 20 min 776 
in 98 % A + 2 % B. Following sample injection, a gradient run (flow rate 1 mL.min-1) was 777 
performed as follows: 0–2 min, isocratic step (98 % A + 2 % B), 2–15 min 98 % A + 2 % B – 80 778 
% A + 20 % B, 15–20 min 80 % A + 20 % B – 57 % A + 43 % B, 20–22 min 57 % A + 43 % B – 100 779 
% B, and 22–25 min 100 % B. Samples were detected on a pulsed electrochemical detector. 780 
 781 
Bacterial size measurement 782 
 783 
HeLa cells in a 6-well plate, treated with siRNA as described above, were infected every two 784 
hours with L2IncDGFP bacteria at a MOI = 0.3. The next day, all wells were detached and fixed 785 
simultaneously in 2 % PFA and 2.5 % glutaraldehyde (Sigma) in PBS. After 25 min, cells were 786 
broken using glass beads, vortexed and syringed (3 times, using 1 mL 26GA x 3/8-inch 787 
syringes). Samples were then analyzed by flow cytometry. An exponential culture of E. coli, 788 
 20 
purified C. trachomatis elementary bodies (i.e. the infectious non-replicative form of the 789 
bacterium) and non-infected cells prepared the same way were used to gate successively for 790 
particles of equal size or smaller than E. coli (thereby excluding non-broken cells), larger than 791 
elementary bodies (thereby excluding non-dividing bacteria), and with positive green 792 
fluorescence (thereby excluding cell debris). The forward-scattered light (FSC-A) was used to 793 
compare bacterial diameters. Each data point represents the mean of at least 400 gated 794 
events. 795 
 796 
Electron microscopy 797 
 798 
One million five hundred thousand cells were transfected with siRNA and infected two days 799 
later. Cells were fixed 30 hpi with 2.5 % glutaraldehyde (v/v) (Electron Microscopy Sciences) 800 
in 0.1 M cacodylate buffer pH 7.4, for 1 h at room temperature. After several washes in 801 
cacodylate they were post-fixed with 1 % osmium tetroxide (w/v) in cacodylate for 1 h. After 802 
several washes with water the cells were progressively dehydrated with increasing 803 
concentrations of ethanol from 25 % to 100 %. The cells were then gradually embedded in 804 
epoxy resin. After overnight polymerization at 60 °C, 50 to 70 nm thin sections were cut in an 805 
ultra-microtome (Ultracut, Leica) and cells were imaged after post-staining with uranyl 806 
acetate and lead citrate in a T12-FEI transmission EM operated at 120kV. 807 
 808 
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 LEGENDS TO THE FIGURES 1042 
 1043 
Figure 1. TG2 transamidase activity increases during C. trachomatis infection along with its 1044 
expression.  1045 
A – Whole cell lysates were prepared with HeLa cells infected or not for 48 h with C. 1046 
trachomatis L2 (multiplicity of infection MOI=1) in the presence or not of BP. In the indicated 1047 
samples CP4d was added 2 h before infection. Cell lysates were run on SDS-PAGE, proteins 1048 
were transferred to a membrane and BP incorporation was revealed with HRP-conjugated 1049 
streptavidin. BP incorporation is enhanced in infected samples, and is inhibited by CP4d. The 1050 
two main bands present in all samples correspond to naturally biotinylated host proteins 1051 
(Haneji & Koide, 1989). After blotting the membrane was stained with Coomassie blue to 1052 
control for equal loading.  1053 
B – Same as in (A), except that where indicated 250 µM doxycycline (doxy, left) or 7 µM 1054 
cycloheximide (CHX, right) were added 24 h or 2 hpi, respectively.  1055 
C – Whole cell lysates were prepared with TG2+/+ and TG2-/- MEFs infected or not for 48 h with 1056 
C. trachomatis L2 in the presence or not of BP, and analyzed as in (A).  1057 
D –Western blot with anti-TG2 antibodies on total cell lysates infected or not with C. 1058 
trachomatis L2 for the indicated time. The histogram displays the mean ± SD of TG2 expression 1059 
relative to actin from four independent experiments, with the results of the Student’s ratio-1060 
paired t-test. NI: not infected.  1061 
E – Cells were infected with C. trachomatis L2 (MOI=1) for 24 or 46 h. Where indicated, 40 µM 1062 
CP4d was added 2 hpi.  tgm2 transcripts were measured by real-time RT-PCR and normalized 1063 
to actin transcripts following the DDCt method. The data are presented as relative mRNA 1064 
levels compared to uninfected cells and shown as the mean ± SD. Each experiment was 1065 
performed in duplicate and repeated at least four times. P-values of Student’s ratio-paired t-1066 
test <0.05 are shown.  1067 
F – Cells were treated for 18 h with the indicated concentration of human recombinant IL-6 1068 
before measuring TG2 transcription relative to actin like in (E). The data are presented as 1069 
relative mRNA levels compared to untreated cells and shown as the mean ± SD. Each 1070 
experiment was performed in duplicate and repeated at least three times. P-values of 1071 
Student’s ratio-paired t-test <0.05 are shown. 1072 
F – Cells were left uninfected or infected with C. trachomatis L2 in the presence of the 1073 
indicated concentration of anti-IL-6 receptor antibodies. Forty-eight h later TG2 transcription 1074 
relative to actin was measured like in (E). The data are presented as relative mRNA levels 1075 
compared to uninfected/untreated cells and shown as the mean ± SD. Each experiment was 1076 
performed in duplicate and repeated at least three times. P-values of Student’s ratio-paired 1077 
t-test <0.05 are shown. 1078 
 1079 
Figure 2. TG2 activity is needed for optimal C. trachomatis developmental and enhances 1080 
hydrosalpinx upon C. muridarum infection in mice.  1081 
A – HeLa cells were pre-treated with the indicated concentrations of CP4d (or DMSO alone) 1082 
for 2 h before being infected with L2incDGFP at MOI=0.15. Thirty hours later the cells were 1083 
disrupted and bacterial titers (IFU=inclusion forming unit) were determined by re-infecting 1084 
fresh HeLa cells as described in the methods. The mean ± SD of three independent 1085 
experiments are shown. P-values of Student’s paired t-test are indicated when <0.05.  1086 
B – HeLa cells were transfected with control siRNA or two siRNAs against TG2. Two days later, 1087 
the efficiency of the silencing was assessed by western blot using anti-TG2 antibodies and anti-1088 
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actin antibodies as loading control (bottom). Duplicate wells were infected with L2incDGFP and 1089 
progeny was analyzed as in (A) (top). The mean ± SD of four independent experiments are 1090 
shown. P-values of Student’s paired t-test are indicated when <0.05. 1091 
C – Same as in (A) except that C. trachomatis serovar L2 (left) or D (right) were grown in 1092 
primary cells isolated from fallopian tubes. For serovar D, IFU were determined 48 hpi. The 1093 
mean ± SD of four to five independent experiments are shown. P-values of Student’s paired t-1094 
test are indicated when <0.05. 1095 
D – HeLa cells were pre-treated with the indicated concentrations of CP4d (or DMSO alone) 1096 
for 2 h before being infected with L2incDGFP at MOI=0.15. Thirty hours later the cells were fixed 1097 
and analyzed by flow cytometry. The percentage of infected cells (left) and the mean 1098 
fluorescence of the infected population (right) ± SD are shown for three independent 1099 
experiments. P-values of Student’s paired t-test are indicated when <0.05. A representative 1100 
field for each condition is shown, scale bar = 10 µm.  1101 
E – Primary epithelial cells isolated from fallopian tubes were pre-treated with the indicated 1102 
concentrations of CP4d (or DMSO alone) for 2 h before being infected with C. trachomatis 1103 
serovar L2 (left) or D (right). Twenty-four hours later the cells were fixed, bacteria were stained 1104 
using FITC-labeled anti-Chlamydia-LPS antibodies, and the mean size of the inclusions 1105 
manually determined using ImageJ, on twenty inclusions per experiment. The mean ± SD of 1106 
three independent experiments are shown. P-values of Student’s paired t-test are indicated 1107 
when <0.05.  1108 
F – Mice were infected intravaginally with 105 IFU of C. muridarum. Twenty-five days later the 1109 
mice were sacrificed and the upper genital tract, from the uterine horn to the oviduct, was 1110 
collected. The right part was used for bacterial burden assessment (top left). The left part was 1111 
rinsed with PBS and observed with a binocular magnifier (right) to determine the hydrosalpinx 1112 
score (bottom left). Each dot represents one mouse, the mean ± SD is shown. P-values of 1113 
Mann-Whitney test are indicated when <0.05.  1114 
 1115 
Figure 3. TG2 controls glucose import.  1116 
A – MEFs were grown for 24 h culture medium complemented with the indicated 1117 
concentration of glucose before being infected with L2 IncDGFP bacteria (MOI = 0.2). Cells were 1118 
disrupted 30 h later and the bacterial titer determined by re-infecting fresh wild type cells. 1119 
The mean ± SD of three independent experiments are shown.  1120 
B – Cells were infected with C. trachomatis L2 (MOI=1) for 24 or 48 h. Where indicated 40 µM 1121 
CP4d was added 2 hpi. GLUT-1 and GLUT-3 transcripts were measured by real-time RT-PCR 1122 
and normalized to actin transcripts following the DDCt method. The data are presented as 1123 
relative mRNA levels compared to uninfected cells and shown as the mean ± SD. Each 1124 
experiment was performed in duplicate and repeated four times. P-values of Student’s ratio-1125 
paired t-test are indicated when <0.05.  1126 
C —Relationship between TGM2 and GLUT-1 (top) and GLUT-3 (bottom) expression across 1127 
265 HGSOCs. Expression comparisons were performed using Spearman’s rank correlation test.  1128 
D —HeLa cells were infected with C. trachomatis L2 (MOI=1) for 24 or 46 h. HIF-1a transcripts 1129 
were measured by real-time RT-PCR and normalized to actin transcripts. The data are 1130 
presented as relative mRNA levels compared to uninfected cells and shown as the mean ± SD. 1131 
Each experiment was performed in duplicate and repeated three times. P-values of Student’s 1132 
ratio-paired t-test are > 0.05.  1133 
 1134 
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E — HeLa cells were transfected with control siRNA or two siRNAs against HIF-1a. Two days 1135 
later, cells were infected with C. trachomatis L2 (MOI=1) for 48 h. The indicated transcripts 1136 
were measured by real-time RT-PCR and normalized to actin transcripts. The data are 1137 
presented as relative mRNA levels compared to uninfected cells and shown as the mean ± SD. 1138 
Each experiment was performed in duplicate and repeated three times. P-values of Student’s 1139 
ratio-paired t-test are indicated when <0.05.  1140 
 1141 
F — TG2-/- MEFs stably transformed or not with the indicated TG2 construct were infected for 1142 
two days with C. trachomatis L2 (MOI=1). Mouse GLUT-1 transcripts were measured by real-1143 
time RT-PCR and normalized to mouse actin transcripts. The data are presented as relative 1144 
mRNA levels compared to uninfected cells and shown as the mean ± SD. Each experiment was 1145 
performed in duplicate and repeated three times. P-values of Student’s ratio-paired t-test are 1146 
indicated when <0.05.  1147 
 1148 
 1149 
Figure 4. GFPT is a substrate of TG2 transamidase activity.  1150 
A – HeLa cells were infected with C. trachomatis (MOI = 1) and 40 µM CP4d was added or not 1151 
2 hpi. After 24 h 0.5 mM BP was added and cells were lysed at 48 hpi. Lysates were 1152 
precipitated with streptavidin-coated beads. After separation with SDS-PAGE, proteins were 1153 
transferred to a membrane and blotted with anti-GFPT antibody followed with HRP-1154 
conjugated secondary antibody.  1155 
B – In vitro assay testing the ability of purified TG2 to crosslink purified rhGFPT1 with BP. 1156 
Samples were incubated for 3 h at 37°C before separation by SDS-PAGE. Proteins were 1157 
transferred to a membrane and BP was revealed using HRP-conjugated streptavidin. rhGFPT1 1158 
is 77.5 kDa.  1159 
C –GFPT1 sequence: glutamine residues identified by mass spectrometry as cross-linked to BP 1160 
are in bold letter .  1161 
D – In vitro assay was performed as described in B using wild type rhGFPT1 (WT), rhGFPT1 1162 
Q58N, rhGFPT1 Q328N or rhGFPT1 Q555N as substrates. The reaction was performed at 37 °C 1163 
for 30 min. After probing with HRP-Streptavidin the membrane was washed and probed with 1164 
anti-GFPT antibodies followed with HRP-conjugated secondary antibodies. The ratio of 1165 
modified protein (streptavidin signal) to the total GFPT is shown, normalized to its value with 1166 
WT rhGFPT1. The mean ± SD of five independent experiments is shown, the p-value of the 1167 
Student’s ratio-paired t-test is indicated when <0.05.  1168 
E – Lysates of cells treated or not for 6 h with ionomycin were incubated at 37 °C for 45 min 1169 
with fructose-6-P and glutamine. The production of glucosamine-6-P was measured using 1170 
HPAEC-PAD. Results of three independent experiments are shown, with mean ± SD, and  p-1171 
value of the Student’s paired t-test is indicated (*P < 0.05).  1172 
 1173 
 1174 
Figure 5. TG2 activation results in increased UDP-GlcNAc production.   1175 
A – Schematic view of the hexosamine biosynthesis pathway. Production of glucosamine-6-P 1176 
by GFPT is the first and rate-limiting step of the pathway that produces UDP-GlcNAc. HK: 1177 
hexokinase; G6PI: glucose-6-P isomerase; GFPT: glutamine:fructose-6-P amidotransferase; 1178 
GNA: glucosamine-6-P N-acetyltransferase; PGM3: phosphoglucomutase 3; UAP: UDP-N-1179 
acetylglucosamine pyrophosphorylase; OGT: O-GlcNAc transferase OGA: O-GlcNAcase; 1180 
GlcNAc: N-acetylglucosamine.  1181 
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B – Endocervical epithelial cells were pre-treated or not with 40 µM CP4d for 2 h before 1182 
addition of the indicated concentration of ionomycin (or an equivalent volume of DMSO) and 1183 
0.5 µM BP. Six hours later whole cell lysates were analyzed by western blot. The membrane 1184 
was first blotted with HRP-conjugated streptavidin to detect TG2 activity, then extensively 1185 
washed and probed with anti-O-GlcNAcylation antibody followed with HRP-conjugated 1186 
secondary antibodies. Last the membrane was probed with anti-actin as a loading control.   1187 
C – The same experimental procedure as described in (B) was applied to HeLa cells treated for 1188 
48 h prior to ionomycin treatment (8 µM) with siRNA control or directed against TG2. 1189 
 1190 
Figure 6. Optimal bacterial growth requires GFPT and prevents UDP-GlcNAc accumulation.  1191 
A – HeLa cells were infected or not (NI) with C. trachomatis (MOI = 1), then lysed 24 or 48 hpi. 1192 
After separation with SDS-PAGE, proteins were transferred to a membrane, probed with anti-1193 
O-GlcNAcylation antibody followed with HRP-conjugated secondary antibodies. After 1194 
extensive washes the membrane was blotted again with anti-GFPT and anti-actin antibodies 1195 
before revelation with HRP-conjugated secondary antibodies.  1196 
B – HeLa cells were infected or not with C. trachomatis (MOI = 1). Twenty-four hours later, 8 1197 
µM ionomycin (or DMSO alone) and 0.5 mM BP were added. After 6 h of treatment, cells were 1198 
lysed and proteins revealed as in (A).  1199 
C – HeLa cells treated for 72 h with siRNA targeting GFPT1 or GFPT2 were lysed. After 1200 
separation with SDS-PAGE, proteins were transferred to a membrane, probed with anti-GFPT 1201 
and anti-actin antibody before revelation with HRP-conjugated secondary antibodies.  1202 
D – HeLa cells were transfected with control siRNA or siRNAs against GFPT or TG2. Two days 1203 
later the cells were infected for the indicated times (MOI=0.3) before fixation, rupture of the 1204 
cells and measurement of bacterial diameter. The mean diameter ± SD and p-values of 1205 
Student’s paired t-test on 4 independent experiments are shown.  1206 
E – HeLa cells treated for 48 h with siRNA targeting GFPT1 or not (siCTRL) were infected with 1207 
C. trachomatis (MOI = 0.15). Thirty hours later cells were fixed and analyzed by flow 1208 
cytometry. The percentage of infected cells (top) and the mean fluorescence of the infected 1209 
population (middle) ) ± SD  are shown for at least four independent experiments. Duplicate 1210 
wells were lysed and used to re-infect fresh HeLa cells to determine the bacterial titer 1211 
(bottom). P-values of Student’s ratio-paired t-test are indicated.  1212 
F – Schematic view of the outcome of TG2 activation in infection. The increase in TG2 1213 
expression and activity in cells infected with C. trachomatis results in the up-regulation of the 1214 
expression of glucose transporters. Increasing quantities of glucose are thus imported in the 1215 
host cytoplasm and redirected to the vacuole, where they fuel bacterial growth. Parallel to 1216 
this transcriptional outcome, the transamidating activity of TG2 targets the host enzyme GFPT, 1217 
thereby boosting the hexosamine biosynthesis pathway. The bacteria consume the resulting 1218 
UDP-GlcNAc, or an intermediate along this pathway, in particular to sustain bacterial division.  1219 
 1220 
Expanded View Figure Legends 1221 
 1222 
 1223 
Figure EV1. TG2 is beneficial for bacterial development (related to Figure 2).  1224 
A – HeLa cells were pre-treated with the indicated concentrations of Cysteamine for 2 h before 1225 
being infected with L2incDGFP at MOI=0.15. Thirty hours later the cells were disrupted and 1226 
bacterial titers (IFU) were determined by re-infecting fresh HeLa cells as described in the 1227 
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methods. The mean ± SD of three independent experiments are shown. P-values of Student’s 1228 
paired t-test are indicated when <0.05.  1229 
B – TG2+/+ and TG2-/- MEFs were infected with L2incDGFP at MOI=0.15. Thirty h later the cells 1230 
were disrupted and bacterial titers were determined by re-infecting fresh TG2 +/+ cells as 1231 
described in the methods. The mean ± SD of five independent experiments and p-values from 1232 
Student’s paired t-test are shown.  1233 
C – To measure bacterial adhesion TG2+/+ and TG2-/- MEFs were incubated at 4 °C for 4 h with 1234 
L2incDGFP at MOI=10 before being washed and fixed as described in the methods. The mean ± 1235 
SD of three independent experiments are shown.  1236 
D – TG2+/+ and TG2-/- MEFs were infected with L2incDGFP at MOI=10 and fixed at the indicated 1237 
time. Extracellular bacteria were differentially labeled as described in the methods. The mean 1238 
± SD of three independent experiments, and p-values from Student’s paired t-test, are shown.  1239 
 1240 
Figure EV2. Infection by C. muridarum activates TG2, which favors bacterial growth (related 1241 
to Figure 2).  1242 
A – Whole cell lysates were prepared with HeLa cells infected or not for 48 h with C. 1243 
muridarum (MOI=1) in the presence or not of BP. Cell lysates were run on SDS-PAGE, proteins 1244 
were transferred to a membrane and BP incorporation was revealed with HRP-conjugated 1245 
streptavidin.  1246 
B – HeLa cells were transfected with siRNA against TG2 for 48 h before being infected in 1247 
duplicates with C. muridarum at MOI=0.15. Thirty hours later one set of cells were disrupted 1248 
and bacterial titers (IFU=inclusion forming unit) were determined by re-infecting fresh HeLa 1249 
cells as described in the methods. The mean ± SD of three independent experiments and p-1250 
values of Student’s paired t-test are shown (top). Duplicate wells were incubated further for 1251 
a total of 48 h before the cells were fixed, permeabilized with 0.3% Triton-X100 and stained 1252 
with rabbit antibodies against C. muridarum GroEL followed with A488-coupled anti-rabbit 1253 
secondary antibodies. Samples were analyzed by flow cytometry, the percentage of infected 1254 
cells (middle) and the mean fluorescence of the infected population (bottom) ± SD are shown 1255 
for three independent experiments, p-values of Student’s paired t-test are indicated. 1256 
 1257 
Figure EV3. GFPT silencing affects bacterial division (related to Figure 6).  1258 
HeLa cells treated for 48 h with siRNA targeting GFPT1 or not (siCTRL) were infected with C. 1259 
trachomatis (MOI = 1), fixed 30 hpi and processed for transmission electron microscopy. Lines 1260 
show example of measured RB diameters. Scale bar = 600 nm. RB diameters were measured 1261 
using ImageJ on > 300 bacteria in one experiment. Each dot represents one RB, the mean value 1262 
± SD and p-value of Student’s paired t-test are indicated. 1263 
 1264 
 1265 









EMBOJ-2019-102166 
Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis   
Benoit Maffei1,2, Marc Laverrière1, Yongzheng Wu1, Sébastien Triboulet1, Stéphanie Perrinet1, 
Magalie Duchateau3, Mariette Matondo3, Robert L. Hollis4, Charlie Gourley4, Jan Rupp5, Jeffrey W. 
Keillor6 and Agathe Subtil1* 
 
APPENDIX 
 
Table of contents: 
• Legends to the supplementary figures 
• Figure  S1. Live bacteria induce TG2 activation in HeLa and MEFs cells. 
• Figure S2. Reduction of bacterial load does not account for the loss of induction of GLUT-1 
and GLUT-3 transcription upon CP4d treatment. 
• Figure S3. Measure of glucosamine-6-P production by GFPT by HPAEC-PAD. 
• Figure S4. Gating steps for the examination of the size of replicative C. trachomatis by flow 
cytometry. 
• Table S1. Candidate TG2 substrates in C. trachomatis infected cells 
• Table S2. Primers used for siRNA, qPCR and mutagenesis 
 
  
Legends 
Figure S1. Live bacteria induce TG2 activation in HeLa and MEFs cells. Related to Figure 1. Before 
addition to HeLa cells the bacterial inoculum was either left untreated (MOI = 1), or filtered through 
of a 0.22 µM filter, or incubated for 30 min at 65 °C to kill the bacteria. The inoculum was applied to 
HeLa cells in the presence or not of BP and 48 h later whole cell lysates were prepared. After separation 
by SDS-PAGE, proteins were transferred to a membrane and BP incorporation was revealed with HRP-
conjugated streptavidin.  
Figure S2. Reduction of bacterial load does not account for the loss of induction of GLUT-1 and GLUT-
3 transcription upon CP4d treatment. Related to Figure 3. HeLa cells were infected or not with C. 
trachomatis (MOI=1) in duplicate per condition. Two hpi CP4d (40 µM) or 24 hpi doxycycline (62.5 
ng.mL-1 ) were added to the culture medium. Forty-eight hpi DNA were extracted from one well to 
measure bacterial load, and RNA were extracted from the duplicate well. Bacterial gDNA (16S RNA) 
measured by real-time RT-PCR was normalized to host gDNA (actin gene) and is expressed relative to 
the infected non-treated culture. GLUT-1 and GLUT-3 transcripts were measured by real-time RT-PCR 
and normalized to actin with the DDCt method as in Fig. 3A. The experiment was performed in 
duplicate and repeated four times, mean ± SD are shown. P-values of the Student’s ratio-paired t-test 
are indicated when <0.05. 
Figure S3. Measure of glucosamine-6-P production by GFPT by HPAEC-PAD. Related to Figure 4. The 
three top panels show the retention times of the different sugars used or produced during the reaction 
when analyzed by HPAEC-PAD. Note that glutamine and glutamate are not retained by this column. A 
cell lysate without addition of fructose-6-P or glutamine is also shown. The bottom two panels display 
an enlargement of the output of the reaction when control or ionomycin treated cell lysates were 
used. The arrows point to the glucosamine-6-P peak. Fructose-6-P was not entirely consumed by the 
reaction. Formation of glucose-6-P was also observed, possibly by GFPT isomerase activity or by 
another cellular enzyme present in the lysate such as glucose-6-P isomerase. 
Figure S4. Gating steps for the examination of the size of replicative C. trachomatis by flow 
cytometry. Related to Figure 6. Exponential cultures of E. coli, density-gradient purified elementary 
bodies, non-infected cells, and cells infected with L2incDGFP at MOI=0.3 for different time points 
(indicated)  were fixed and treated as described in the methods section. The top dot plots describe 
how the first three samples were used to gate the region of interest that contains mostly replicative C. 
trachomatis (excluded regions are hatched). An increase in the number of replicative bacteria, and a 
decrease in their size (FSC-A value) were observed when increasing infection time. 
 
 
 




Table S1: Candidate TG2 substrates in C. trachomatis infected cells 
The list displays streptavidin-bound proteins identified by mass spectrometry in the infected samples 
only in the presence of BP (first 37 entries) or more abundant in the presence of BP than in its absence 
(last 25 entries, Log2([Mean intensity with BP]/[Mean intensity without BP]) and p-values are shown). 
UniProt ID Protein Gene Protein description log2 P-value 
Q8NE71-2 ABCF1 ABCF1  ATP-binding cassette sub-family F member 1 NA NA 
O95831-3 AIFM1 AIFM1 Apoptosis-inducing factor 1 NA NA 
P50995-2 ANX11 ANXA11 Annexin A11 NA NA 
P84077 ARF1 ARF1 ADP-ribosylation factor 1  NA NA 
Q13510 ASAH1 ASAH1 Acid ceramidase NA NA 
Q12797-10 ASPH ASPH Aspartyl/asparaginyl beta-hydroxylase NA NA 
P36542-2 ATPG ATP5C1 ATP synthase subunit gamma NA NA 
O95816 BAG2 BAG2 BAG family molecular chaperone regulator NA NA 
Q13185 CBX3 CBX3 Chromobox protein homolog 3 NA NA 
Q9Y696 CLIC4 CLIC4 Chloride intracellular channel protein 4  NA NA 
Q16555-2 DPYL2 DPYSL2 Dihydropyrimidinase-related protein NA NA 
P55884 EIF3B EIF3B Eukaryotic translation initiation factor 3 subunit B NA NA 
P02751-4 FINC FN1 Fibronectin NA NA 
G3V1Q4 G3V1Q4 SEPT7 Septin 7 NA NA 
Q9HAV0 GBB4 GNB4 Guanine nucleotide-binding protein subunit beta NA NA 
O94808 GFPT2 GFPT2  Glutamine--fructose-6-phosphate aminotransferase NA NA 
P08754 GNAI3 GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha NA NA 
H3BSW3 H3BSW3 APRT  Adenine phosphoribosyltransferase NA NA 
P68871 HBB HBB Hemoglobin subunit beta NA NA 
A0A087WZW8 IGKV3-11 IGKV3-11 Ig kappa chain C region NA NA 
Q15181 IPYR PPA1 Inorganic pyrophosphatase NA NA 
J3QLE5 J3QLE5 SNRPN Small nuclear ribonucleoprotein-associated protein N NA NA 
K7ENG2 K7ENG2 U2AF2 Splicing factor U2AF 65 kDa subunit NA NA 
P17931 LEG3 LGALS3 Galectin-3 NA NA 
C9JIG9 OSR1 OSXR1 Serine/threonine-protein kinase OSR1 NA NA 
P17858 PFKAL PFKL ATP-dependent 6-phosphofructokinase NA NA 
E9PQ98 PRMT1 PRMT1 Protein arginine N-methyltransferase 1 NA NA 
P62195-2 PRS8 PSMC5 26S proteasome regulatory subunit 8  NA NA 
O00487 PSDE PSMD14 26S proteasome non-ATPase regulatory subunit NA NA 
Q16401-2 PSMD5 PSMD5 26S proteasome non-ATPase regulatory subunit 5 NA NA 
Q06203 PUR1 PPAT Amidophosphoribosyltransferase NA NA 
P17812-2 PYRG1 CTPS1 CTP synthase 1 NA NA 
P43487-2 RANG RANBP1 Ran-specific GTPase-activating protein NA NA 
Q9P2E9-2 RRBP1 RRBP1 Ribosome-binding protein 1 NA NA 
P56192 SYMC MARS Methionine--tRNA ligase NA NA 
O95497 VNN1 VNN1 Pantetheinase NA NA 
E9PRD9 VNN2 VNN2 Vascular non-inflammatory molecule 2  NA NA 
P08243-2 ASNS ASNS Asparagine synthetase 7,62 1,81E-08 
P30508 HLA-C HLA-C HLA class I histocompatibility antigen, Cw-12 alpha chain 9,05 4,07E-08 
P35613-2 BASI BSG Basigin 2,33 1,85E-05 
P10909-4 CLUS CLU Clusterin 2,13 3,91E-05 
P49368 TCPG CCT3 T-complex protein 1 subunit gamma 1,83 3,99E-04 
O15427 MOT4 SLC16A3 Monocarboxylate transporter 4  1,93 6,21E-04 
E9PLL6 RPL27A RPL271  60S ribosomal protein L27a 1,36 9,12E-04 
Q15233 NONO NONO Non-POU domain-containing octamer-binding protein 1,26 1,21E-03 
P30837 AL1B1 ALDH1B1 Aldehyde dehydrogenase X 1,98 1,50E-03 
E9PLA9 CAPRIN1 CAPRIN Caprin-1 1,47 1,61E-03 
P17987 TCPA TCP1 T-complex protein 1 subunit alpha 1,91 2,84E-03 
P39019 RS19 RPS19 40S ribosomal protein S19 1,44 3,74E-03 
O43143 DHX15 DHX15 
Putative pre-mRNA-splicing factor ATP-dependent RNA 
helicase  1,00 4,00E-03 
P61586 RHOA RHOA Transforming protein RhoA 1,01 4,49E-03 
C9J9K3 RPSA RPSA 40S ribosomal protein SA 1,07 4,91E-03 
A0A087WXM6 RPL17 RPL17 60S ribosomal protein L17  1,01 5,48E-03 
P38919 EIF4A3 EIF4A3 Eukaryotic initiation factor 4A-III 1,08 7,23E-03 
P00505 AATM GOT2 Aspartate aminotransferase, mitochondrial 1,11 8,63E-03 
P27105 STOM STOM Erythrocyte band 7 integral membrane protein 1,01 9,61E-03 
A0A096LNZ9 ISG15 ISG15 Ubiquitin-like protein ISG15 1,25 1,10E-02 
E9PEX6 DLD DLD Dihydrolipoyl dehydrogenase, mitochondrial 1,08 1,66E-02 
Q10589-2 BST2 BST2 Bone marrow stromal antigen 2 1,15 2,37E-02 
Q06210 GFPT1 GFPT1 Glutamine--fructose-6-phosphate aminotransferase 3,22 2,49E-02 
A0A087WVM3 CYR61 CYR61 Protein CYR61 1,34 2,75E-02 
Q13162 PRDX4 PRDX4 Peroxiredoxin-4 1,13 2,88E-02 
 
 Table S2: Primer sequences used for siRNA, qPCR and mutagenesis 
Experiment Target Sequence 
siRNA 
TG2.1 GGGCGAACCACCUGAACAAdTdT 
TG2.2 CAGUUCGAGGAUGGAAUCCUGGAUAdTdT 
HIF1a.1 AAGUCUGCAACAUGGAAGGUAdTdT 
HIF1a.2 UUCUCCGAACGUGUCACGUdTdT 
GFPT1.1 GACAGAUUGUGGAGUUCAUdTdT 
GFPT1.2 CCUUGGUGGAGAGAGUUAUdTdT 
GFPT1.3 GUGACUUCCUGGACAGAAAdTdT 
GFPT2.1 GUUCCAAGUUUGCGUAUAAdTdT      
GFPT2.2 GACCGAAUUUCACUACAAAdTdT  
GFPT2.3 CCAUCGCCAAGCUGAUUAAdTdT 
qPCR 
α-actin GGACTTCGAGCAAGAGATGG 
GCAGTGATCTCCTTCTGCATC 
 Chlamydia 
16S RNA 
TGGATGAGGCATGCAAGTA 
TACTAACCCTTCCGCCACTAAA 
Mouse 18S 
RNA 
TAACGAACGAGACTCTGGCAT 
CGGACATCTAAGGGCATCACAG 
TG2 TAAGAGATGCTGTGGAGGAG 
CGAGCCCTGGTAGATAAA 
GLUT-1 AACTCTTCAGCCAGGGTCCAC 
CACAGTGAAGATGATGAAGAC 
GLUT-3 CACAGGTTTTGTGCCCATGTA 
ACCCCGCAGGGCAGTAG 
Mutagenesis 
Q58N GGGAAGCCAATGCCTGCAAAATCAATCTTATTAAGAAGAAAGGAAAAGT 
ACTTTTCCTTTCTTCTTAATAAGTTGATTTTGCAGGCATTGGCTTCCC 
Q326N CGAGCTGTGCAAACACTCAATATGGAACTCCAGCAGATC 
GATCTGCTGGAGTTCCATATTGAGTGTTTGCACAGCTCG 
Q548N 
CGAAATTCAGAAACTAGCAACAGAACTTTATCATAATAAGTCAGTTCTGATAATG 
CATTATCAGAACTGACTTATTATGATAAAGTTCTGTTGCTAGTTTCTGAATTTCG 
 
 
 
 
 
